

In re application of: Paolo Renzi
Application No.: 09/719,737
Filed: 06/29/2001
For: ANTISENSE OLIGONUCLEOTIDES FOR TREATING ATOPIC DISEASES AND NEOPLASTIC CELL PROLIFERATION

Group No.: 1635
Examiner: Karen A. Lacourciere

REMARKS

Applicant respectfully submits that Groups I – V should be examined together. Applicant respectfully submits that the five groups of invention share a special technical feature in that the antisense oligonucleotides of each group are preferably used concurrently with antisense oligonucleotides of at least one other groups for the treatment or the prevention of asthma, allergies, hypereosinophilia, inflammation or cancer thereby providing a more complete treatment.

The present invention does not only relate to the antisense oligonucleotides of a single group of invention, although it can be used as such, but preferably the invention relates to antisense oligonucleotides of the five groups of invention used concurrently.

Applicant respectfully submits that the special technical features shared by each group of invention is that each group of invention relate to antisense oligonucleotides that can be used with other antisense oligonucleotides from the other groups of invention to provide a more complete treatment. Each of these groups of invention are therefore believed to be so linked as to form a single general inventive concept, all linked together by this special technical feature. Each antisense oligonucleotide from each group of invention is used for the same purpose, that is, for treating or preventing asthma, allergies, hypereosinophilia, inflammation or cancer.

It is respectfully submitted that restricting the search to a single group within the invention or having the Applicant pay additional fees for having other groups within the invention prosecuted in separate divisional applications is unfair to the Applicant. Applicant believes that the groups of invention connected by the special technical feature identified above should all be searched together.

In view of the above and foregoing, it is respectfully solicited that all the groups be searched together as they are linked by the special technical feature defined above.

In re application of: Paolo Renzi
Application No.: 09/719,737
Filed: 06/29/2001
For: ANTISENSE OLIGONUCLEOTIDES FOR TREATING ATOPIC DISEASES AND NEOPLASTIC CELL
PROLIFERATION

Group No.: 1635
Examiner: Karen A. Lacourciere

FEE AUTHORIZATION

Should any fees be associated with the submission be required, the Commissioner is authorized to
such deficiencies to our Deposit Account No. 50-0850. Any overpayments should be credited to said
Deposit Account.

Date: 12/24/02

Customer No.: 26770

Respectfully submitted,



David S. Resnick (Reg. No. 34,235)
NIXON PEABODY LLP
101 Federal Street
Boston, MA 02110
Tel. (617) 345-6057